Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lessened by Private Management Group Inc.

Private Management Group Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 211,383 shares of the biopharmaceutical company’s stock after selling 206,514 shares during the period. Private Management Group Inc.’s holdings in Gilead Sciences were worth $19,525,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the third quarter valued at approximately $25,000. HHM Wealth Advisors LLC boosted its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter worth $29,000. Finally, Crews Bank & Trust bought a new stake in Gilead Sciences in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $99.65 on Thursday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market capitalization of $124.19 billion, a PE ratio of 1,107.22, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The stock has a fifty day moving average of $92.71 and a 200-day moving average of $86.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $100.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $2.29 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GILD shares. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Wells Fargo & Company boosted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Monday. Finally, The Goldman Sachs Group boosted their price target on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.